

### Ordering Physician or Delegate to Complete

#### Test Selected

DetermaRx  EGFR (tumor tissue analysis - Exon 18-21)

**DetermaRx Intended Use:** Improving the quality of post-surgical treatment decisions by identifying patients at highest risk of 5-year mortality, and therefore the most likely to benefit from adjuvant chemotherapy, in stage IA, IB and IIA (8th edition) non-squamous non-small cell lung cancer patients whose tumors have been fully resected and are candidates for chemotherapy.

#### Ordering Physician Information

Physician Name \_\_\_\_\_  
 Organization Name \_\_\_\_\_  
 NPI Number \_\_\_\_\_  
 Street Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_  
 Postal Code \_\_\_\_\_ Country \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_  
 Email Address (For online report access) \_\_\_\_\_

Report Delivery  Encrypted Email  Secured Fax

You are authorizing the electronic delivery of test results by Oncocyte in accordance with the Health Insurance Portability and Accountability Act (HIPAA) and the rules reflected in the HITECH Act.

#### Patient Information

Last Name \_\_\_\_\_ Suffix \_\_\_\_\_  
 First Name \_\_\_\_\_ Middle Initial \_\_\_\_\_  
 Sex  F  M  Undisclosed Date of Birth (DOB mm/dd/yyyy) \_\_\_\_\_  
 Last 4-digits of SSN \_\_\_\_\_ Medical Record # \_\_\_\_\_  
 Street Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_  
 Postal Code \_\_\_\_\_ Country \_\_\_\_\_  
 Phone \_\_\_\_\_  
 Email Address (For Invoicing) \_\_\_\_\_  
 Patient Diagnosis (ICD-10 Codes) \_\_\_\_\_  
 Hospital Status at Time of Specimen Collection:  
 In-Office Procedure  Hospital Outpatient  Hospital Inpatient (>24 hour)  
 Discharge Date (mm/dd/yyyy) \_\_\_\_\_  Not Yet Discharged

#### Pathology Laboratory Information

Oncocyte to request specimen from Pathology  Ordering Physician to request specimen from Pathology  
 Contact Name \_\_\_\_\_  
 Organization Name \_\_\_\_\_  
 Street Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_  
 Postal Code \_\_\_\_\_ Country \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_

#### Ordering Physician Signatures & Attestations

I, the undersigned, attest that I ordered the DetermaRx test and/or the EGFR test for my eligible patient, and this order is appropriately documented in the Patient Medical record. The test(s) is/are medically necessary and reasonable to provide information to allow me to personalize treatment for my patient's medical condition. This patient has a non-squamous NSCLC with a tumor size < 5cm, and there are no positive lymph nodes (i.e. American Joint Committee on Cancer Eighth Edition Stages I and IIA); the patient is sufficiently healthy to tolerate chemotherapy, and adjuvant platinum containing chemotherapy is being considered for the patient. I have provided Oncocyte / Razor Genomics, Inc. with my patient's current insurance information, and I understand that Oncocyte / Razor Genomics, Inc. will be billing the patient's insurance company and accepting assignment on this claim. The patient and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) and requested and consented for this test to be performed.

X

Treating Physician Signature (or Authorized Delegate) \_\_\_\_\_ Date (mm/dd/yyyy) \_\_\_\_\_

\*Delegate has the authorization to sign supporting forms and documents on behalf of the Treating Physician for Oncocyte orders.

#### Billing Information

Billing Type:  Medicare  Medicaid/IPA  Commercial  Self-Pay

Primary Insurance Name \_\_\_\_\_

Plan Name \_\_\_\_\_

Insurance ID# \_\_\_\_\_ Group# \_\_\_\_\_

Patient relationship with subscriber  Self  Spouse  Dependent

Subscriber Name (if not patient) \_\_\_\_\_

Address \_\_\_\_\_

Sex  F  M  Undisclosed Date of Birth (DOB mm/dd/yyyy) \_\_\_\_\_

Secondary Insurance Name \_\_\_\_\_

Plan Name \_\_\_\_\_

Insurance ID# \_\_\_\_\_ Group# \_\_\_\_\_

Patient relationship with subscriber  Self  Spouse  Dependent

Subscriber Name (if not patient) \_\_\_\_\_

Address \_\_\_\_\_

Sex  F  M  Undisclosed Date of Birth (DOB mm/dd/yyyy) \_\_\_\_\_

Attach a copy of both sides of primary/secondary insurance cards.

If Patient needs financial assistance, call 1.844.662.6298 or visit Oncocyte.com to obtain the Financial Assistance Form.

#### Specimen Information

IASLC TNM Staging T \_\_\_\_\_ N \_\_\_\_\_ M \_\_\_\_\_  
 (when available)

IASLC Overall Stage  IA  IB  IIA  
 (select one)

FFPE Block ID (Case ID) \_\_\_\_\_

Specimen Collection Date (mm/dd/yyyy) \_\_\_\_\_

Number of primary non-squamous NSCLC lesions to be tested \_\_\_\_\_

### Pathology to Complete

Review and update your contact information above and fill in the sample information. Select a surgical FFPE specimen (not a biopsy) with a tumor area greater than 25% of the block's total tissue area, without regard to cell density. The FFPE specimen must be non-squamous NSCLC in a stage IA, IB, or IIA.

#### Specimen Type Submitted\*

Block  Please return specimen to the above address if submitting block  
 Slides # of slides sent

FFPE Block(s) Cross-Section ID (Case Affix) \_\_\_\_\_

Date Block(s) Removed from Storage: (mm/dd/yyyy) \_\_\_\_\_

Completed by X \_\_\_\_\_

Date (mm/dd/yyyy) \_\_\_\_\_